ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Argenx Follows up Phase III Success with Giant €785M Global Offering
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Business Wire
Genmab enters multiyear antibody partnership with Argenx — MedWatch
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
Argenx's Potential Blockbuster Gets FDA Nod for Autoimmune Disease
Argenx: Next Phase Of Growth With Efgartigimod And ARGX-117 (NASDAQ:ARGX) | Seeking Alpha
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy | Argenx
Genmab expands immunology reach in argenx pact
ARGENX SE Form 6-K Current Report Filed 2023-01-09
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Press release on the reopening of trading in ARGENX | FSMA
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Karen Gluck - Quality Control Editor - argenx | LinkedIn
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
ELITE 2023 Marketing Team VYVGART Brand Launch Team of argenx | PM360
SEC Filing | argenx
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
argenx on X: "Today we announced the continuation of our chronic inflammatory demyelinating polyneuropathy (CIDP) program following interim analysis of the Phase 2/3 ADHERE trial. Learn more here: https://t.co/0vgXZk0o0u https://t.co/iv5KRcJfH8" / X
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis | Business Wire
SEC Filing | argenx
Corporate Presentation June 2023
Myasthenia Gravis Foundation of America, Inc. - argenx announces positive topline results from Phase 3 ADAPT trial for gMG. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia
